Zydus Cadila gets USFDA nod to market generic antihistamine tablets
The drug will be manufactured at the group's manufacturing facility in Ahmedabad
 "Zydus Cadila gets USFDA nod to market generic antihistamine tablets")
premium
Drug firm Zydus Cadila on Wednesday said it has received nod from the US health regulator to market generic antihistamine Meclizine hydrochloride tablets.
The company has received final approval from the United States Food and Drug Administration (USFDA) to market Meclizine hydrochloride tablets in the strengths of 12.5 mg and 25 mg, the company said in a statement.
The drug will be manufactured at the group's manufacturing facility in Ahmedabad, it added.
Meclizine is an antihistamine that is used to prevent and treat nausea, vomiting, and dizziness caused by motion sickness. It may also be used to reduce dizziness and loss of balance (vertigo) caused by inner ear problems, Zydus Cadila said.
The group now has 292 approvals and has so far filed over 390 abbreviated new drug applications (ANDA) since the commencement of its filing process, it added.
Shares of Cadila Healthcare, the listed entity of the group, were trading at Rs 367.20per scrip on the BSE, up 0.07 per cent over previous close.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%